Q2 2024 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2024-08-15 · accession 0001892134-24-000004
$2.14B
Reported value
49
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $234.9M | 11.0% | 12,226,943 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $222.1M | 10.4% | 6,495,392 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $181.5M | 8.49% | 988,460 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $153.5M | 7.18% | 10,617,062 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $104.1M | 4.87% | 10,109,279 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $97.4M | 4.55% | 2,371,304 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $92.0M | 4.30% | 3,632,604 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $81.7M | 3.82% | 8,785,284 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $79.1M | 3.70% | 1,754,834 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $78.5M | 3.67% | 1,039,405 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $67.2M | 3.14% | 3,731,067 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $54.3M | 2.54% | 2,165,591 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $47.9M | 2.24% | 3,314,349 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $43.4M | 2.03% | 3,687,867 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $43.1M | 2.02% | 1,587,527 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $38.7M | 1.81% | 997,455 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $38.3M | 1.79% | 16,216,216 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $37.6M | 1.76% | 871,974 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $35.7M | 1.67% | 875,667 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $33.6M | 1.57% | 1,561,230 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $32.9M | 1.54% | 8,157,385 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $29.3M | 1.37% | 4,142,855 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $24.3M | 1.14% | 770,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $24.0M | 1.12% | 1,502,788 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $22.1M | 1.03% | 373,100 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $22.0M | 1.03% | 7,381,090 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $21.8M | 1.02% | 1,148,591 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $17.5M | 0.82% | 425,000 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $16.1M | 0.75% | 4,623,324 | Common | SOLE |
| 15678U128 | CERE1EUR | CEREVEL THERAPEUTICS HLDNG I | $16.1M | 0.75% | 393,000 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $15.8M | 0.74% | 4,401,371 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $13.4M | 0.63% | 1,152,456 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $13.3M | 0.62% | 832,220 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $12.8M | 0.60% | 3,010,727 | Common | SOLE |
| 03828A101 | APLT | APPLIED THERAPEUTICS INC | $10.7M | 0.50% | 2,286,135 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $10.0M | 0.47% | 3,062,558 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $8.0M | 0.37% | 1,000,000 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $8.0M | 0.37% | 2,958,579 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $7.9M | 0.37% | 936,576 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $7.6M | 0.36% | 470,338 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $7.6M | 0.36% | 285,331 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $7.3M | 0.34% | 1,069,244 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $6.7M | 0.31% | 2,867,750 | Common | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $4.5M | 0.21% | 2,088,889 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $4.4M | 0.20% | 500,333 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $4.0M | 0.19% | 1,195,179 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $3.7M | 0.17% | 108,762 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $1.0M | 0.05% | 245,692 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $290,815 | 0.01% | 264,377 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.